Catalent Pharma and CTC BIO to partner in South Korea
Monday, September 17, 2012
Catalent Pharma Solutions, a Somerset, N.J.-based developer of solutions and drug delivery technology, and CTC Bio, a drug and service provider based in Seoul, South Korea, have entered into a collaboration to provide optimal solutions to South Korean pharmaceutical companies seeking to commercialize solid oral dose and controlled release products in the U.S. and Europe.
Combining CTC Bio’s position in the region with Catalent’s expertise in controlled release formulations, manufacturing network and broad experience in global product launches will provide South Korean companies with access to international markets.
“South Korea is a highly innovative region, developing new products and effective pharmaceutical formulations,” said H.R. Jeon, CSO of CTC Bio. “This collaboration with Catalent provides South Korean pharmaceutical customers with better access to the leading provider of innovative controlled release drug delivery technologies and supply capabilities. Catalent’s breadth of services and reputation for successful new product launches in international markets makes them an ideal partner for us and our clients/partners in South Korea.”